Savara (NASDAQ:SVRA) Sees Strong Trading Volume Following Insider Buying Activity

Savara Inc (NASDAQ:SVRA) shares saw strong trading volume on Wednesday after an insider bought additional shares in the company. 5,254,916 shares were traded during trading, an increase of 318% from the previous session’s volume of 1,257,429 shares.The stock last traded at $3.15 and had previously closed at $2.94.

Specifically, Director Joseph S. Mccracken purchased 20,000 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was bought at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the purchase, the director now directly owns 210,837 shares in the company, valued at approximately $621,969.15. This trade represents a 10.48 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SVRA. Evercore ISI restated an “in-line” rating and issued a $5.00 target price (down from $7.00) on shares of Savara in a research note on Wednesday, November 13th. HC Wainwright reduced their price target on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Finally, JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Savara in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.17.

Savara Trading Up 6.5 %

The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The firm has a market cap of $537.17 million, a P/E ratio of -7.23 and a beta of 1.02. The stock has a 50 day moving average of $3.82 and a 200 day moving average of $4.16.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11). As a group, equities research analysts predict that Savara Inc will post -0.45 EPS for the current year.

Institutional Trading of Savara

A number of institutional investors have recently modified their holdings of SVRA. CANADA LIFE ASSURANCE Co bought a new stake in shares of Savara during the 1st quarter valued at about $35,000. Choreo LLC bought a new position in shares of Savara in the 2nd quarter worth about $59,000. DRW Securities LLC purchased a new position in Savara during the 2nd quarter valued at about $62,000. Virtu Financial LLC bought a new stake in Savara during the third quarter worth about $67,000. Finally, Principal Financial Group Inc. grew its holdings in Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after purchasing an additional 6,973 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.